Strengthening Growth and Technological Advancements
Newcells Biotech, a prominent drug discovery partner renowned for its cutting-edge in vitro models and bespoke assay services, has announced securing an additional £1.2 million in funding. The investment was provided by long-term partners Mercia Ventures, Northstar Ventures, and North East Finance, marking another step in the company’s commitment to enhancing predictive models for human outcomes in medical research.
This fresh injection of capital follows a period of significant growth for Newcells in 2023 and 2024. The company recently unveiled a state-of-the-art imaging suite designed to accelerate the generation of critical data for drug development. The funding will enable Newcells to further expand its customer base, form strategic partnerships, and strengthen its international market presence. The organization aims to meet the growing demand for new approach methods (NAMs), which are gaining traction as viable alternatives to traditional drug discovery techniques.
Strategic Contributions and Leadership
The additional funding was raised through Mercia Ventures’ Northern Venture Capital Trusts and regional funds, including the North East Venture Fund, North East Innovation Fund, and Finance for Business North East Fund. All these initiatives are supported by the European Regional Development Fund, emphasizing the importance of regional innovation in global medical advancements.
As part of this strategic move, Newcells Biotech has welcomed Dr. Mark Carnegie-Brown as the new Chairman of the Board. With over three decades of leadership experience in the pharmaceutical industry, Dr. Carnegie-Brown brings a wealth of knowledge to Newcells. His previous roles include Vice President of Malvern Panalytical and President of Concept Life Sciences. His expertise is expected to guide the company through its ambitious commercial strategy and ongoing technological advancements.
Advancing Drug Discovery Through NAMs
Newcells Biotech’ focus on NAMs aligns with the evolving landscape of drug development. The U.S. FDA’s Modernization Act 2.0, passed in 2023, has heightened interest in alternatives to animal testing. The company’s advanced in vitro tissue models replicate human physiological processes, offering pharmaceutical and biotech firms reliable data to enhance decision-making and clinical translation.
Currently, Newcells provides sophisticated models of the retina, kidney, and lung, alongside customized services that cater to specific industry needs. By offering innovative solutions, Newcells aims to accelerate the development and market entry of new medicines, ultimately improving patient outcomes worldwide.
This milestone underlines Newcells Biotech’s commitment to revolutionizing drug discovery through innovative technologies and strategic partnerships. With its continued focus on expansion and leadership in NAMs, the company is poised to play a pivotal role in the future of medical research and pharmaceutical innovation.
